Latest blog articles
-
What does the term ‘MOCCA’ evoke in your mind, a kind of coffee or a specific brand? This Kat randomly asked this question to her friends currently at the Max Planck Institute for Innovation and Competition Munich. Most of them regarded ‘MOCCA’ as a kind of coffee instead of a specific brand except...
-
Nobuki Yamamoto, a Japanese contemporary artist, made an eye-catching work of ‘goldfish swimming in a phone booth’ (‘Work 1’) by December 2000 at the latest. In October 2011, a student organisation called ‘Goldfish Club’ at Kyoto University of Art and Design produced Work 2 and exhibited it for a...
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
About 100 British officials will arrive in Brussels today to start the mammoth negotiations on the future relationship between the EU and the UK. The two sides are poles apart. The UK wants regulatory detachment from the EU while the EU insists or regulatory alignment.
-
Recently, Chanel Co., Ltd. lost a trade mark infringement case regarding its ‘Double C’ logo in China. The full text of the decision can be visited via here (Google translatable). The case has drawn wide attention and, mostly, negative comments. Does this seemingly-counterintuitive loss indeed, well...
-
The European Union prides itself for being based on the rule of law. Indeed, the success and longevity of the EU as an integration project can be partly explained by, on the one hand, the willingness of Member States to abide by the obligations that stem from the Treaties and, on the other, the...
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...
